Geneva, June 22 -- International Clinical Trials Registry received information related to the study (NCT07646210) titled 'HiCM-188 Cell Therapy in Adults With Advanced Heart Failure Undergoing Heart Bypass Surgery' on June 9.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: HELP Therapeutics Co., Ltd.
Condition:
Advanced Heart Failure
Ischemic Heart Failure
Intervention:
Drug: HiCM-188 Cells
Recruitment Status: Not recruiting
Phase: Phase 1/Phase 2
Date of First Enrollment: September 2026
Target Sample Size: 12
Countries of Recruitment:
United States
To know more, visit https://clinicalt...